| Predictor | Breast Cancer Screening | Bowel Cancer Screening | Hip Fracture Prevention | CVD Prevention | ||||
|---|---|---|---|---|---|---|---|---|
| % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | % (95% CI) | ORa (95% CI) | |
| Age, y | ||||||||
| 50-54 | 86 (77-92) | 0.6 (0.3-1.0) | 89 (81-95) | 0.6 (0.3-1.0) | 80 (71-88) | 1.2 (0.7-2.2) | 70 (59-79) | 0.7 (0.4-1.3) |
| 55-59 | 90 (82-95) | 0.6 (0.3-1.1) | 95 (88-98) | 0.5 (0.3-0.8) | 83 (73-90) | 1.0 (0.6-1.8) | 62 (51-72) | 0.5 (0.3-1.0) |
| 60-64 | 98 (93-100) | 0.9 (0.5-1.6) | 98 (93-100) | 0.7 (0.4-1.3) | 87 (79-92) | 1.3 (0.7-2.2) | 75 (66-83) | 0.9 (0.5-1.7) |
| 65-70 | 95 (88-98) | 1.0 | 100 (96-100) | 1.0 | 82 (72-89) | 1.0 | 74 (63-83) | 1.0 |
| P value | .12 | .05 | .73 | .13 | ||||
| Sex | ||||||||
| Male | 92 (88-95) | 1.0 | 94 (90-97) | 1.0 | 83 (78-88) | 1.0 | 67 (60-73) | 1.0 |
| Female | 93 (89-97) | 1.0 (0.7-1.6) | 97 (93-99) | 1.5 (1.0-2.2) | 84 (77-89) | 1.0 (0.7-1.6) | 73 (66-80) | 1.3 (0.9-2.0) |
| P valueb | .81 | .058 | .84 | .18 | ||||
| Educationc | ||||||||
| Lower | 97 (93-99) | 1.0 | 98 (94-100) | 1.0 | 86 (79-92) | 1.0 | 78 (69-85) | 1.0 |
| Higher | 91 (87-94) | 0.6 (0.4-1.0) | 94 (91-97) | 0.5 (0.3-0.8) | 82 (77-87) | 0.8 (0.5-1.1) | 66 (60-72) | 0.6 (0.4-0.9) |
| P valued | .03 | .002 | .19 | .026 | ||||
| Past experiencee | ||||||||
| No | – | – | 96 (93-98) | 1.0 (0.6-1.4) | 84 (79-98) | 0.9 (0.5-1.7) | 69 (64-74) | 1.0 (0.6-1.8) |
| Yes | – | – | 94 (89-97) | 1.0 | 80 (66-90) | 1.0 | 76 (61-86) | 1.0 |
| P valued | – | .85 | .82 | .98 | ||||
CVD = cardiovascular disease; OR = odds ratio.
↵a OR calculated from multivariable logistic regression with the proportional odds assumption, across all response levels excluding unknown. OR >1.0 indicates higher estimates of effectiveness.
↵b df = 3.
↵c df = 1.
↵d Lower = primary or secondary school only. Higher = post-school qualification.
↵e Prior bowel cancer screening, diagnosis of osteoporosis or current medication for osteoporosis, and history of vascular disease. Breast cancer screening—only 5 women had never been screened so not included in the mode.